Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enli Liu

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|March 15, 2021
GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK CellsEnli Liu, Sonny O T Ang, Lucila Kerbauy, et al.
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Nature Medicine|January 5, 2024
Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Cancer Cell|August 22, 2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyAlexander Biederstädt, Rafet Basar, Jeong-Min Park, et al.
Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Blood Advances|July 28, 2020
Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cellsRafet Basar, May Daher, Nadima Uprety, et al.
Frontiers in Immunology|May 21, 2021
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHDMayela Mendt, May Daher, Rafet Basar, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|March 15, 2021
GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK CellsEnli Liu, Sonny O T Ang, Lucila Kerbauy, et al.
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Nature Medicine|January 5, 2024
Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Cancer Cell|August 22, 2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyAlexander Biederstädt, Rafet Basar, Jeong-Min Park, et al.
Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Blood Advances|July 28, 2020
Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cellsRafet Basar, May Daher, Nadima Uprety, et al.
Frontiers in Immunology|May 21, 2021
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHDMayela Mendt, May Daher, Rafet Basar, et al.
Pageof 7